Successful Treatment of Pemphigus Vulgaris with Ofatumumab
Rapp, M.; Pentland, A.; Richardson, C.
Journal of Drugs in Dermatology Jdd 17(12): 1338-1339
2018
ISSN/ISBN: 1545-9616 PMID: 30586270 Document Number: 17672
Rituximab is a chimeric anti-CD20 monoclonal antibody that is very effective in treating patients with pemphigus vulgaris. Though infrequent, the development of human anti-chimeric antibodies in patients receiving rituximab results in loss of efficacy. Ofatumumab is a second-generation fully-human anti-CD20 monoclonal antibody currently used to treat chronic lymphocytic leukemia. We report a case of a patient with pemphigus vulgaris successfully treated with ofatumumab after developing human anti-chimeric antibodies to rituximab.
Document emailed within 1 workday